Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 1, 2005, Pages 18-23

  Andin, Josefine ^a,b   Enz, Albert ^c   Gentsch, Conrad ^c   Marcusson, Jan ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Excitatory amino acid carrier 1; Glutamate; In situ hybridisation; Transporters

Indexed keywords

CHOLINESTERASE INHIBITOR; COMPLEMENTARY RNA; DIGOXIGENIN; EXCITATORY AMINO ACID; GLUTAMATE TRANSPORTER; MESSENGER RNA; RIVASTIGMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD VENTRAL HORN; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; CHOLINESTERASE INHIBITORS; DENTATE GYRUS; GENE EXPRESSION; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; NEOCORTEX; NEURONS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; RATS; RNA, MESSENGER; SYMPORTERS;

EID: 10844225168     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080966     Document Type: Article

References (22)

1. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P: Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;73:665-671.
2. Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Steardo L, Kendrick KM, Cuomo V: Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain Res 2001;910:182-186.
3. Neary D, Snowden JS, Mann DM, Bowen DM, Sims NR, Northen B, Yates PO, Davison AN: Alzheimer's disease: A correlative study. J Neurol Neurosurg Psychiatry 1986;49:229-237.
4. Tsien JZ, Huerta PT, Tonegawa S: The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996;87:1327-1338.
5. Aigner TG: Pharmacology of memory: Cholinergic-glutamatergic interactions. Curr Opin Neurobiol 1995;5:155-160.
6. Fisher JL, Dani JA: Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component. Neuropharmacology 2000;39:2756-2769.
7. Farlow M: A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 2002;14:93-126.
8. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
9. Trabace L, Coluccia A, Gaetani S, Tattoli M, Cagiano R, Pietra C, Kendrick KM, Cuomo V: In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res 2000;865:268-271.
10. Rogers J, Morrison JH: Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 1985;5:2801-2808.
11. Maragos WF, Greenamyre TJ, Penney JB, Young AB: Glutamate dysfunction in Alzheimer's disease: A hypothesis. Trends Neurosci 1987;65-68.
12. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. San Diego, Academic Press Inc, 1986.
13. Bjoras M, Gjesdal O, Erickson JD, Torp R, Levy LM, Ottersen OP, Degree M, Storm-Mathisen J, Seeberg E, Danbolt NC: Cloning and expression of a neuronal rat brain glutamate transporter. Brain Res Mol Brain Res 1996;36:163-168.
14. Dijkman H, Mentzel S, de Jong MSA, Assmann K: RNA in situ hybridization using digoxigenin-labeled cRNA probes. Biochemica 1995;2:21-25.
15. Torp R, Hoover F, Danbolt NC, Storm-Mathisen J, Ottersen OP: Differential distribution of the glutamate transporters GLT1 and rEAAC1 in rat cerebral cortex and thalamus: An in situ hybridization analysis. Anat Embryol (Berl) 1997;195:317-326.
16. Liste I, Bernard V, Bloch B: Acute and chronic acetylcholinesterase inhibition regulates in vivo the localization and abundance of muscarinic receptors m2 and m4 at the cell surface and in the cytoplasm of striatal neurons. Mol Cell Neurosci 2002;20:244-256.
17. Kanai Y, Hediger MA: Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992;360:467-471.
18. Csernansky JG, Bardgett ME, Sheline YI, Morris JC, Olney JW: CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology 1996;46:1715-1720.
19. Scott HL, Pow DV, Tannenberg AE, Dodd PR: Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci 2002;22:RC206.
20. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F: Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47:305-313.
21. Kaufer D, Friedman A, Seidman S, Soreq H: Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission. Chem Biol Interact 1999;119-120:349-360.
22. Delescluse C, Ledirac N, Li R, Piechocki MP, Hines RN, Gidrol X, Rahmani R: Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells. Biochem Pharmacol 2001;61:399-407.